567 related articles for article (PubMed ID: 10371507)
21. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
22. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
23. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
26. On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients.
van Oijen M; Bins A; Elias S; Sein J; Weder P; de Gast G; Mallo H; Gallee M; Van Tinteren H; Schumacher T; Haanen J
Clin Cancer Res; 2004 Jul; 10(14):4754-60. PubMed ID: 15269149
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
28. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
[TBL] [Abstract][Full Text] [Related]
29. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
30. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
31. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
32. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
[TBL] [Abstract][Full Text] [Related]
33. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
34. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
[TBL] [Abstract][Full Text] [Related]
35. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
[TBL] [Abstract][Full Text] [Related]
37. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
Maczek C; Berger TG; Schuler-Thurner B; Schultz ES; Hamann A; Dunbar PR; Cerundolo V; Steinkasserer A; Schuler G
Int J Cancer; 2005 Jun; 115(3):450-5. PubMed ID: 15688371
[TBL] [Abstract][Full Text] [Related]
38. An antigen-targeted approach to adoptive transfer therapy of cancer.
Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
[TBL] [Abstract][Full Text] [Related]
39. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
Kang X; Robbins PF; Fitzgerald EB; Wang R; Rosenberg SA; Kawakami Y
Cancer Res; 1997 Jan; 57(2):202-5. PubMed ID: 9000554
[TBL] [Abstract][Full Text] [Related]
40. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.
Speeckaert R; van Geel N; Luiten RM; van Gele M; Speeckaert M; Lambert J; Vermaelen K; Tjin EP; Brochez L
Anticancer Res; 2011 Nov; 31(11):3697-703. PubMed ID: 22110189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]